495 related articles for article (PubMed ID: 17273909)
1. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
Pan J; Heiser A; Marget M; Steinmann J; Kabelitz D
Gene Ther; 2005 May; 12(9):742-50. PubMed ID: 15729371
[TBL] [Abstract][Full Text] [Related]
3. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice].
Li XH; Tang L; Liu D; Sun HM; Zhou CC; Tan LS; Wang LP; Zhang PD; Zhang SQ
Ai Zheng; 2006 Oct; 25(10):1221-6. PubMed ID: 17059764
[TBL] [Abstract][Full Text] [Related]
6. The enhanced anti-angiogenic and antitumor effects of combining flk1-based DNA vaccine and IP-10.
Lu XL; Jiang XB; Liu RE; Zhang SM
Vaccine; 2008 Oct; 26(42):5352-7. PubMed ID: 18723067
[TBL] [Abstract][Full Text] [Related]
7. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
9. Hydrodynamics-based gene delivery of naked DNA encoding fetal liver kinase-1 gene effectively suppresses the growth of pre-existing tumors.
Yazawa H; Murakami T; Li HM; Back T; Kurosaka K; Suzuki Y; Shorts L; Akiyama Y; Maruyama K; Parsoneault E; Wiltrout RH; Watanabe M
Cancer Gene Ther; 2006 Nov; 13(11):993-1001. PubMed ID: 16763608
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
Funahashi Y; Wakabayashi T; Semba T; Sonoda J; Kitoh K; Yoshimatsu K
Oncol Res; 1999; 11(7):319-29. PubMed ID: 10757446
[TBL] [Abstract][Full Text] [Related]
11. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
12. The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade.
Nisancioglu MH; Betsholtz C; Genové G
Cancer Res; 2010 Jun; 70(12):5109-15. PubMed ID: 20501841
[TBL] [Abstract][Full Text] [Related]
13. Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.
Gali-Muhtasib H; Sidani M; Geara F; Mona AD; Al-Hmaira J; Haddadin MJ; Zaatari G
Int J Oncol; 2004 May; 24(5):1121-31. PubMed ID: 15067333
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
[TBL] [Abstract][Full Text] [Related]
16. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
[TBL] [Abstract][Full Text] [Related]
17. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
[TBL] [Abstract][Full Text] [Related]
19. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine.
Scappaticci FA; Nolan GP
Anticancer Res; 2003; 23(2B):1165-72. PubMed ID: 12820367
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
